Clinical trial · Interventional
Pelvic Physical Therapy for Sexual Dysfunction in Gynecologic Oncology Survivors
Feasibility of Pelvic Physical Therapy for Sexual Dysfunction in Gynecologic Oncology Survivors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260930-000001
Summary
Brief summary (as posted)
The purpose of this research study is to investigate the use of pelvic physical therapy for gynecologic cancer survivors who report sexual dysfunction. Physical therapy experts believe that a full 10-week regimen is necessary for true improvement of symptoms. Investigators aim to see if this tense regimen is feasible for survivors. Investigators also aim to see if patients have an improvement in their sexual function and quality of life.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gynecologic Cancer | Malignant Female Reproductive System Neoplasm | ALIAS | 0.90 |
| Sexual Dysfunction | — | UNRESOLVED | — |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Control Arm | Other | — | UNRESOLVED |
| European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) | Other | — | UNRESOLVED |
| Exit Interview | Other | — | UNRESOLVED |
| Female Sexual Function Index (FSFI) | Other | — | UNRESOLVED |
| Physical Therapy Arm | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- PLACEBO_COMPARATOR
- label
- Control Arm
- description
- Educational pamphlet with resources for sexual dysfunction
- interventionNames
- Other: Control Arm
- type
- EXPERIMENTAL
- label
- Physical Therapy Arm
- description
- Physical therapy for sexual dysfunction.
- interventionNames
- Other: Physical Therapy Arm
- Other: European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)
- Other: Female Sexual Function Index (FSFI)
- Other: Exit Interview
Primary outcomes (3)
- measure
- Accrual to Study Intervention
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * History of cervical, ovarian/fallopian tube/primary peritoneal, uterine, or vulvar/vaginal cancer, regardless of stage or amount of prior therapy. Patients must have completed radiation therapy 12 weeks prior enrollment. Patients must be at least 12 weeks remote from surgery. There is no minimum time after completion of chemotherapy for enrollment. There is no upper limit of time from treatment. * History of treatment for gynecological cancer - surgery, radiation, chemotherapy, or combination of therapies. * Screen positive for sexual dysfunction based on answers to the Brief Sexual Symptom Checklist for Women. A patient screens positive if they answer "no" to the first question (Are you satisfied with your sexual function?) and if they select any answer other than "a" in the third question (Mark which of the following problems you are having). The other questions do not impact whether a patient screens positive or negative. They do not have an impact on study eligibility. * English-speaking. Due to the developmental nature of this study, assessing feasibility with a small number of patients, we do not have all response tools and questionnaires translated into multiple languages. In a future larger study, it will be important to translate all documents into multiple languages in order to include non-English speakers. * Age ≥18 years Exclusion Criteria: * Active pelvic infection * Presence of vaginal fistula * Deemed not suitable for PPT based on physician assessment. If there is suspicion for infection, disease recurrence, or other concerning medical findings that necessitate further evaluation and work up at that time. * Evidence of active cancer
References
Publications (0)
Data not yet available